Breast surgeon leading the IEO programme founded by Umberto Veronesi, pioneer of breast conservation.
Paolo Veronesi is Director of Breast Surgery at IEO, the European Institute of Oncology, in Milan and Professor at the University of Milan. His specialisms are breast surgery, sentinel node biopsy and surgical de-escalation. He leads the programme founded by Umberto Veronesi, the pioneer of breast conservation, continuing the institute's tradition of de-escalation from quadrantectomy to sentinel node biopsy and axillary sparing. His papers include the long-term follow-up of the IBCSG 23-01 trial of axillary dissection versus no dissection in patients with sentinel-node micrometastases, a historical perspective on axillary surgery in breast cancer, and a ten-year follow-up of sentinel node biopsy after neoadjuvant treatment. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial | The Lancet Oncology | 2018 |
| Axillary surgery in breast cancer: An updated historical perspective | Seminars in Oncology | 2020 |
| Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up | European Journal of Surgical Oncology | 2021 |
Shares European journal of surgical oncology, European Society of Surgical Oncology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares IEO (European Institute of Oncology), Sentinel lymph node biopsy, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Sentinel lymph node biopsy, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Sentinel lymph node biopsy, HR-positive / HER2-negative breast cancer.
Shares IEO (European Institute of Oncology), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Sentinel lymph node biopsy, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Sentinel lymph node biopsy, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Sentinel lymph node biopsy, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.